Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical trials without meta-analysis or original data.
PubMed 42579353 · doi:10.14336/AD.2025.1308
What was done
This narrative review synthesized preclinical and clinical evidence evaluating metformin's potential to slow cardiovascular aging. The authors examined molecular pathways (including AMPK activation and mitochondrial complex I inhibition) and reviewed findings from observational studies and randomized trials, such as UKPDS, TAYSIDE, GIPS-III, REMOVAL, and GOMET.
What was found
The abstract reports no numerical values or effect sizes. Preclinical literature indicates metformin enhances mitochondrial biogenesis, suppresses chronic inflammation, promotes autophagy, and modulates epigenetic clocks; however, randomized controlled trials show inconsistent results for both clinical and surrogate cardiovascular endpoints.
Why it matters
Metformin is a primary candidate for pharmacological geroprotection. Understanding the disconnect between robust preclinical mechanisms and mixed clinical trial outcomes is critical for designing targeted longevity and cardiovascular trials in non-diabetic older adults.
Limits
The paper is a narrative review without quantitative meta-analysis. The underlying evidence base is constrained by small sample sizes, short follow-up periods in clinical trials, sexual dimorphism in drug response, hormetic dosing dynamics, and a lack of validated cardiovascular endpoints specific to biological aging.
Cited by
- supports Metformin stimulates the activation of AMP-activated protein kinase (AMPK).